TY - BOOK PY - 2015 DA - 2015// TI - Fiscal sustainability of health systems: bridging health and finance perspectives PB - OECD Publishing CY - Paris UR - https://doi.org/10.1787/9789264233386-en DO - 10.1787/9789264233386-en ID - ref1 ER - TY - JOUR AU - Baumol, W. J. PY - 1967 DA - 1967// TI - Macroeconomics of unbalanced growth: the anatomy of urban crisis JO - Am Econ Rev VL - 57 ID - Baumol1967 ER - TY - JOUR AU - Batesa, L. AU - Santerre, R. PY - 2013 DA - 2013// TI - Does the U.S. health care sector suffer from Baumol’s cost disease? Evidence from the 50 states JO - J Health Econ VL - 32 UR - https://doi.org/10.1016/j.jhealeco.2012.12.003 DO - 10.1016/j.jhealeco.2012.12.003 ID - Batesa2013 ER - TY - JOUR AU - Hartwig, J. PY - 2008 DA - 2008// TI - What drives health care expenditure? Baumol’s model of ‘unbalanced growth’ revisited JO - J Health Econ VL - 27 UR - https://doi.org/10.1016/j.jhealeco.2007.05.006 DO - 10.1016/j.jhealeco.2007.05.006 ID - Hartwig2008 ER - TY - JOUR AU - Scannell, J. AU - Blanckley, A. AU - Boldon, H. PY - 2012 DA - 2012// TI - Diagnosing the decline in pharmaceutical R&D efficiency JO - Nat Rev Drug Discov VL - 11 UR - https://doi.org/10.1038/nrd3681 DO - 10.1038/nrd3681 ID - Scannell2012 ER - TY - JOUR AU - Paul, S. M. AU - Mytelka, D. M. AU - Dunwiddie, C. T. AU - Persinger, C. C. AU - Munos, B. H. AU - Lindborg, S. R. AU - Schacht, A. L. PY - 2010 DA - 2010// TI - How to improve R&D productivity: the pharmaceutical industry's grand challenge JO - Nat Rev Drug Discov VL - 9 UR - https://doi.org/10.1038/nrd3078 DO - 10.1038/nrd3078 ID - Paul2010 ER - TY - JOUR AU - Mahlich, J. AU - Yurtoglu, B. PY - 2019 DA - 2019// TI - Returns on different types of investment in the global pharmaceutical industry JO - Manag Decis Econ VL - 40 UR - https://doi.org/10.1002/mde.2977 DO - 10.1002/mde.2977 ID - Mahlich2019 ER - TY - CHAP AU - Solow, R. PY - 1987 DA - 1987// TI - We’d better watch out BT - New York Times Book Review ID - Solow1987 ER - TY - JOUR AU - Acemoglu, D. AU - Autor, D. AU - Dorn, D. AU - Hanson, G. AU - Price, B. PY - 2016 DA - 2016// TI - Import competition and the great US employment sag of the 2000s JO - J Labor Econ VL - 34 UR - https://doi.org/10.1086/682384 DO - 10.1086/682384 ID - Acemoglu2016 ER - TY - STD TI - Rotman D. The productivity paradox- Why brilliant AI technologies are not leading to widespread growth and prosperity: MIT Technology review; 2018. Available: https://www.technologyreview.com/2018/06/18/104277/the-productivity-paradox/ UR - https://www.technologyreview.com/2018/06/18/104277/the-productivity-paradox/ ID - ref10 ER - TY - JOUR AU - Pammolli, F. AU - Magazzini, L. AU - Riccaboni, M. PY - 2011 DA - 2011// TI - The productivity crisis in pharmaceutical R&D JO - Nat Rev Drug Discov VL - 10 UR - https://doi.org/10.1038/nrd3405 DO - 10.1038/nrd3405 ID - Pammolli2011 ER - TY - JOUR AU - Hay, M. AU - Thomas, D. AU - Craighead, J. AU - Economides, C. AU - Rosenthal, J. PY - 2014 DA - 2014// TI - Clinical development success rates for investigational new drugs JO - Nat Biotechnol VL - 32 UR - https://doi.org/10.1038/nbt.2786 DO - 10.1038/nbt.2786 ID - Hay2014 ER - TY - STD TI - FDA. Adaptive designs for clinical trials of drugs and biologics: guidance for industry. Washington; 2019. available: https://www.fda.gov/media/78495/download UR - https://www.fda.gov/media/78495/download ID - ref13 ER - TY - STD TI - EMA. Guidance for companies considering the adaptive pathways approach. 2016; EMA/527726/2016. Available: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-companies-considering-adaptive-pathways-approach_en.pdf. Accessed 1 Aug 2020. UR - https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-companies-considering-adaptive-pathways-approach_en.pdf ID - ref14 ER - TY - BOOK PY - 2019 DA - 2019// TI - FDA modernizes clinical trial designs and approaches for drug development, proposing new guidance on the use of adaptive designs and master protocols ID - ref15 ER - TY - JOUR AU - Sydes, M. AU - Parmar, M. AU - Mason, M. AU - Clarke, N. AU - Amos, C. AU - Anderson, J. AU - Bono, J. AU - Dearnaley, D. AU - Dwyer, J. AU - Green, C. AU - Jovic, G. AU - Ritchie, A. AU - Russell, J. AU - Sanders, K. AU - Thalmann, G. AU - James, N. PY - 2013 DA - 2013// TI - Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial JO - Trials VL - 13 UR - https://doi.org/10.1186/1745-6215-13-168 DO - 10.1186/1745-6215-13-168 ID - Sydes2013 ER - TY - JOUR AU - Chevret, S. PY - 2012 DA - 2012// TI - Bayesian adaptive clinical trials: a dream for statisticians only? JO - Stat Med VL - 31 UR - https://doi.org/10.1002/sim.4363 DO - 10.1002/sim.4363 ID - Chevret2012 ER - TY - JOUR AU - Fogel, D. PY - 2018 DA - 2018// TI - Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review JO - Contemp Clin Trials Commun VL - 11 UR - https://doi.org/10.1016/j.conctc.2018.08.001 DO - 10.1016/j.conctc.2018.08.001 ID - Fogel2018 ER - TY - JOUR AU - Hwang, T. J. AU - Carpenter, D. AU - Lauffenburger, J. C. AU - Wang, B. AU - Franklin, J. M. AU - Kesselheim, A. S. PY - 2016 DA - 2016// TI - Failure of investigational drugs in late-stage clinical development and publication of trial results JO - JAMA Intern Med VL - 176 UR - https://doi.org/10.1001/jamainternmed.2016.6008 DO - 10.1001/jamainternmed.2016.6008 ID - Hwang2016 ER - TY - JOUR AU - Thorlund, K. AU - Haggstrom, J. AU - Park, J. AU - Mills, E. PY - 2018 DA - 2018// TI - Key design considerations for adaptive clinical trials: a primer for clinicians JO - BMJ VL - 360 UR - https://doi.org/10.1136/bmj.k698 DO - 10.1136/bmj.k698 ID - Thorlund2018 ER - TY - JOUR AU - Cerqueira, F. P. AU - Jesus, A. M. C. AU - Cotrim, M. D. PY - 2020 DA - 2020// TI - Adaptive design: a review of the technical, statistical, and regulatory aspects of implementation in a clinical trial JO - Ther Innov Regul Sci VL - 54 UR - https://doi.org/10.1007/s43441-019-00052-y DO - 10.1007/s43441-019-00052-y ID - Cerqueira2020 ER - TY - JOUR AU - DiMasi, J. AU - Grabowski, H. AU - Hansen, R. PY - 2016 DA - 2016// TI - Innovation in the pharmaceutical industry: new estimates of R&D costs JO - J Health Econ VL - 47 UR - https://doi.org/10.1016/j.jhealeco.2016.01.012 DO - 10.1016/j.jhealeco.2016.01.012 ID - DiMasi2016 ER - TY - JOUR AU - Hartford, A. AU - Thomann, M. AU - Chen, X. AU - Miller, E. AU - Bedding, A. AU - Jorgens, S. AU - Liu, L. AU - Chen, L. AU - Morgan, C. PY - 2020 DA - 2020// TI - Adaptive designs: results of 2016 survey on perception and use JO - Ther Innov Regul Sci VL - 54 UR - https://doi.org/10.1007/s43441-019-00028-y DO - 10.1007/s43441-019-00028-y ID - Hartford2020 ER - TY - JOUR AU - Adams, C. AU - Brantner, V. PY - 2006 DA - 2006// TI - Estimating the cost of new drug development: is it really $802 million? JO - Health Aff VL - 25 UR - https://doi.org/10.1377/hlthaff.25.2.420 DO - 10.1377/hlthaff.25.2.420 ID - Adams2006 ER - TY - BOOK AU - Mestre-Ferrandiz, J. AU - Sussex, J. AU - Towse, A. PY - 2012 DA - 2012// TI - The R&D Cost of a New Medicine PB - Office of Health Economics CY - London ID - Mestre-Ferrandiz2012 ER - TY - JOUR AU - Lakdawalla, D. PY - 2018 DA - 2018// TI - Economics of the pharmaceutical industry JO - J Econ Lit VL - 56 UR - https://doi.org/10.1257/jel.20161327 DO - 10.1257/jel.20161327 ID - Lakdawalla2018 ER - TY - JOUR AU - McCutchen, W. PY - 1993 DA - 1993// TI - Estimating the impact of the R&D tax credit on strategic groups in the pharmaceutical industry JO - Res Policy VL - 22 UR - https://doi.org/10.1016/0048-7333(93)90004-2 DO - 10.1016/0048-7333(93)90004-2 ID - McCutchen1993 ER - TY - BOOK PY - 2017 DA - 2017// TI - Health at a Glance: Business enterprise expenditure for pharmaceutical R&D (BERD) and government budgets for health-related R&D (GBARD) PB - OECD publishing CY - Paris ID - ref28 ER - TY - JOUR AU - Lichtenberg, F. PY - 2004 DA - 2004// TI - Sources of U.S. longevity increase, 1960–2001 JO - Quart Rev Econ Finance VL - 44 UR - https://doi.org/10.1016/j.qref.2004.05.005 DO - 10.1016/j.qref.2004.05.005 ID - Lichtenberg2004 ER - TY - STD TI - US Bureau of Labor Statistics. Historical Consumer Price Index for all Urban Consumers (CPI-U), available at:https://www.bls.gov/cpi/tables/supplemental-files/historical-cpi-u-202001.pdf, Accessed 15 June 2020. UR - https://www.bls.gov/cpi/tables/supplemental-files/historical-cpi-u-202001.pdf ID - ref30 ER - TY - JOUR AU - Kairalla, J. A. AU - Coffey, C. S. AU - Thomann, M. A. PY - 2012 DA - 2012// TI - Adaptive trial designs: a review of barriers and opportunities JO - Trials VL - 13 UR - https://doi.org/10.1186/1745-6215-13-145 DO - 10.1186/1745-6215-13-145 ID - Kairalla2012 ER - TY - JOUR AU - Kanavos, P. AU - Tzouma, V. AU - Flannelly, C. PY - 2018 DA - 2018// TI - The impact of regulatory accelerated approval schemes and Htas on access to new oncology medicines: evidence from 11 countries JO - Value Health VL - 21 UR - https://doi.org/10.1016/j.jval.2018.04.244 DO - 10.1016/j.jval.2018.04.244 ID - Kanavos2018 ER - TY - JOUR AU - Eger, S. AU - Mahlich, J. PY - 2014 DA - 2014// TI - Pharmaceutical regulation in Europe and its impact on corporate R&D JO - Heal Econ Rev VL - 4 UR - https://doi.org/10.1186/s13561-014-0023-5 DO - 10.1186/s13561-014-0023-5 ID - Eger2014 ER - TY - JOUR AU - Vernon, J. A. PY - 2003 DA - 2003// TI - The relationship between price regulation and pharmaceutical profit margins JO - Appl Econ Lett VL - 10 UR - https://doi.org/10.1080/1350485032000090776 DO - 10.1080/1350485032000090776 ID - Vernon2003 ER - TY - JOUR AU - Budish, E. AU - Roin, B. AU - Williams, H. PY - 2015 DA - 2015// TI - Do firms underinvest in long-term research? Evidence from Cancer clinical trials JO - Am Econ Rev VL - 105 UR - https://doi.org/10.1257/aer.20131176 DO - 10.1257/aer.20131176 ID - Budish2015 ER - TY - JOUR AU - Narayan, V. AU - Mohwinckel, M. AU - Pisano, G. PY - 2013 DA - 2013// TI - Beyond magic bullets: true innovation in health care JO - Nat Rev Drug Discov VL - 12 UR - https://doi.org/10.1038/nrd3944 DO - 10.1038/nrd3944 ID - Narayan2013 ER - TY - JOUR AU - Jack, C. R. AU - Bennett, D. A. AU - Blennow, K. PY - 2018 DA - 2018// TI - NIA-AA research framework: toward a biological definition of Alzheimer’s disease JO - Alzheimers Dement VL - 14 UR - https://doi.org/10.1016/j.jalz.2018.02.018 DO - 10.1016/j.jalz.2018.02.018 ID - Jack2018 ER - TY - JOUR AU - Mehta, D. AU - Jackson, R. AU - Paul, G. AU - Shi, J. AU - Sabbagh, M. PY - 2017 DA - 2017// TI - Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010-2015 JO - Expert Opin Investig Drugs VL - 26 UR - https://doi.org/10.1080/13543784.2017.1323868 DO - 10.1080/13543784.2017.1323868 ID - Mehta2017 ER - TY - STD TI - Manski C. Adaptive Partial Drug Approval. A Health Policy Proposal. Econ Voice. 2009;6(4):1-5. ID - ref39 ER - TY - JOUR AU - Eichler, H. -. G. AU - Oye, K. AU - Baird, L. AU - Abadie, E. AU - Brown, J. AU - Drum, C. AU - Ferguson, J. AU - Garner, S. AU - Honig, P. AU - Hukkelhoven, M. AU - Lim, J. AU - Lim, R. AU - Lumpkin, M. AU - Neil, G. AU - O’Rourke, B. AU - Pezalla, E. AU - Shoda, D. AU - Seyfert-Margolis, V. AU - Sigal, E. AU - Sobotka, J. AU - Tan, D. AU - Unger, T. AU - Hirsch, G. PY - 2012 DA - 2012// TI - Adaptive licensing: taking the next step in the evolution of drug approval JO - Clin Pharmacol Ther VL - 91 UR - https://doi.org/10.1038/clpt.2011.345 DO - 10.1038/clpt.2011.345 ID - Eichler2012 ER - TY - JOUR AU - Schuster, B. AU - Brhlikova, P. AU - Heath, J. AU - McGettigan, P. PY - 2019 DA - 2019// TI - The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018 JO - PLoS Med VL - 16 UR - https://doi.org/10.1371/journal.pmed.1002873 DO - 10.1371/journal.pmed.1002873 ID - Schuster2019 ER - TY - BOOK AU - Garattini, S. AU - Gøtzsche, P. AU - Jefferson, T. PY - 2016 DA - 2016// TI - Scientists voice concerns about adaptive pathways ID - Garattini2016 ER - TY - STD TI - EMA. Adaptive pathways reply to Garattini S, Gøtzsche P, Jefferson T et al. 2016. Available: https://www.ema.europa.eu/en/documents/other/ema-response-letter-group-scientists-clarifying-concept-adaptive-pathways_en.pdf. Accessed 1 Aug 2020. UR - https://www.ema.europa.eu/en/documents/other/ema-response-letter-group-scientists-clarifying-concept-adaptive-pathways_en.pdf ID - ref43 ER - TY - BOOK PY - 2016 DA - 2016// TI - Rafal Swierzewski, adaptive pathways workshop ID - ref44 ER - TY - JOUR AU - Ermisch, M. AU - Bucsics, A. AU - Vella Bonanno, P. PY - 2016 DA - 2016// TI - Payers’ views of the changes arising through the possible adoption of adaptive pathways JO - Front Pharmacol VL - 7 UR - https://doi.org/10.3389/fphar.2016.00305 DO - 10.3389/fphar.2016.00305 ID - Ermisch2016 ER - TY - BOOK PY - 2016 DA - 2016// TI - Adaptive pathways: EMA still leaves open questions unanswered ID - ref46 ER - TY - JOUR AU - Cummings, J. AU - Feldman, H. H. AU - Scheltens, P. PY - 2019 DA - 2019// TI - The “rights” of precision drug development for Alzheimer’s disease JO - Alzheimers Res Ther VL - 11 UR - https://doi.org/10.1186/s13195-019-0529-5 DO - 10.1186/s13195-019-0529-5 ID - Cummings2019 ER - TY - JOUR AU - Lexchin, J. PY - 2015 DA - 2015// TI - Post-market safety warnings for drugs approved in Canada under the notice of compliance with conditions policy JO - Br J Clin Pharmacol VL - 79 UR - https://doi.org/10.1111/bcp.12552 DO - 10.1111/bcp.12552 ID - Lexchin2015 ER - TY - JOUR AU - Frank, C. AU - Himmelstein, D. U. AU - Woolhandler, S. PY - 2014 DA - 2014// TI - Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals JO - Health Aff VL - 33 UR - https://doi.org/10.1377/hlthaff.2014.0122 DO - 10.1377/hlthaff.2014.0122 ID - Frank2014 ER - TY - JOUR AU - Olson, M. PY - 2004 DA - 2004// TI - Are novel drugs more risky for patients than less novel drugs? JO - J Health Econ VL - 23 UR - https://doi.org/10.1016/j.jhealeco.2004.03.007 DO - 10.1016/j.jhealeco.2004.03.007 ID - Olson2004 ER - TY - JOUR AU - Arnardottir, A. H. AU - Haaijer-Ruskamp, F. M. AU - Straus, S. M. AU - Eichler, H. G. AU - Graeff, P. A. AU - Mol, P. G. PY - 2011 DA - 2011// TI - Additional safety risk to exceptionally approved drugs in Europe? JO - Br J Clin Pharmacol VL - 72 UR - https://doi.org/10.1111/j.1365-2125.2011.03995.x DO - 10.1111/j.1365-2125.2011.03995.x ID - Arnardottir2011 ER - TY - JOUR AU - Grabowski, H. AU - Vernon, J. AU - Thomas, L. PY - 1978 DA - 1978// TI - Estimating the effects of regulation on innovation: an international comparative analysis of the pharmaceutical industry JO - J Law Econ VL - 24 UR - https://doi.org/10.1086/466914 DO - 10.1086/466914 ID - Grabowski1978 ER - TY - JOUR AU - Peltzman, S. PY - 1973 DA - 1973// TI - An evaluation of consumer protection: the 1962 drug amendments JO - J Polit Econ VL - 81 UR - https://doi.org/10.1086/260107 DO - 10.1086/260107 ID - Peltzman1973 ER - TY - JOUR AU - Wiggins, S. PY - 1981 DA - 1981// TI - Product quality regulation and new drug introductions: some new evidence from the 1970s JO - Rev Econ Stat VL - 63 UR - https://doi.org/10.2307/1935858 DO - 10.2307/1935858 ID - Wiggins1981 ER - TY - BOOK AU - Grabowski, H. AU - Vernon, J. PY - 1983 DA - 1983// TI - The Regulation of Pharmaceuticals: Balancing the Benefits and Risks PB - American Enterprise Institute for Public Policy Research CY - Washington DC ID - Grabowski1983 ER - TY - JOUR AU - Blanchard, P. AU - Huiban, J. -. P. AU - Musolesi, A. AU - Sevestre, P. PY - 2013 DA - 2013// TI - Where there is a will, there is a way? Assessing the impact of obstacles to innovation JO - Ind Corp Chang VL - 22 UR - https://doi.org/10.1093/icc/dts027 DO - 10.1093/icc/dts027 ID - Blanchard2013 ER - TY - JOUR AU - Blind, K. AU - Petersen, S. AU - Riillo, C. PY - 2017 DA - 2017// TI - The impact of standards and regulation on innovation in uncertain markets JO - Res Policy VL - 46 UR - https://doi.org/10.1016/j.respol.2016.11.003 DO - 10.1016/j.respol.2016.11.003 ID - Blind2017 ER - TY - BOOK PY - 2016 DA - 2016// TI - Better regulations for innovation-driven investment at EU level: commission staff working document ID - ref58 ER - TY - STD TI - European Commission. The innovation principle. Brussels; 2019. Available: https://ec.europa.eu/info/sites/info/files/research_and_innovation/knowledge_publications_tools_and_data/documents/ec_rtd_factsheet-innovation-principle_2019.pdf UR - https://ec.europa.eu/info/sites/info/files/research_and_innovation/knowledge_publications_tools_and_data/documents/ec_rtd_factsheet-innovation-principle_2019.pdf ID - ref59 ER - TY - BOOK PY - 2020 DA - 2020// TI - Pharmaceutical Strategy - Timely patient access ID - ref60 ER - TY - JOUR AU - Light, D. W. AU - Lexchin, J. R. PY - 2012 DA - 2012// TI - Research and development: what do we get for all that money? JO - BMJ VL - 345 UR - https://doi.org/10.1136/bmj.e4348 DO - 10.1136/bmj.e4348 ID - Light2012 ER - TY - JOUR AU - Batta, A. AU - Kalra, B. S. AU - Khirasaria, R. PY - 2020 DA - 2020// TI - Trends in FDA drug approvals over last 2 decades: an observational study JO - J Fam Med Prim Care VL - 9 UR - https://doi.org/10.4103/jfmpc.jfmpc_578_19 DO - 10.4103/jfmpc.jfmpc_578_19 ID - Batta2020 ER - TY - JOUR AU - Kashoki, M. AU - Hanaizi, Z. AU - Yordanova, S. AU - Veselý, R. AU - Bouygues, C. AU - Llinares, J. AU - Kweder, S. L. PY - 2020 DA - 2020// TI - A comparison of EMA and FDA decisions for new drug marketing applications 2014-2016: concordance, discordance, and why JO - Clin Pharmacol Ther VL - 107 UR - https://doi.org/10.1002/cpt.1565 DO - 10.1002/cpt.1565 ID - Kashoki2020 ER -